Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsLTS:0JSY +1.86%80 EV-to-EBITDA is 14.31 as of Jul. 19, 2026, which is 25% above its 10-year median of 11.41. GuruFocus rates LTS:0JSY with a GF Score™ of 80/100 and a GF Value™ of $270.12 (Fairly Valued). The stock has 6 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Labcorp Holdings ranks better than 52.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Labcorp Holdings's enterprise value is $29,512 Mil.
Labcorp Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2,063 Mil. Therefore, Labcorp Holdings's EV-to-EBITDA for today is 14.31.
The historical rank and industry rank for Labcorp Holdings's EV-to-EBITDA or its related term are showing as below:
LTS:0JSY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.78 Med: 11.41 Max: 18.5
Current: 14.31
During the past 13 years, the highest EV-to-EBITDA of Labcorp Holdings was 18.50. The lowest was 5.78. And the median was 11.41.
LTS:0JSY's EV-to-EBITDA is ranked better than 52.14% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.72
vs LTS:0JSY: 14.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labcorp Holdings's PE Ratio (TTM) for today is calculated as:
Labcorp Holdings's share price for today is $282.00.
Labcorp Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Labcorp Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Labcorp Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's EV-to-EBITDA falls into.
Labcorp Holdings's current Enterprise Value is $29,512 Mil.
Labcorp Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,063 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a EV-to-EBITDA of 14.31 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labcorp Holdings. This is 25% above median its historical median of 11.41. Over the past decade, Labcorp Holdings' EV-to-EBITDA has ranged from 5.78 to 18.50. According to the industry distribution chart, Labcorp Holdings ranks #56 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 47.9%.
Is Labcorp Holdings' EV-to-EBITDA too high?
Labcorp Holdings' current EV-to-EBITDA of 14.31 is 25% above median its 10-year median of 11.41. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 18.50. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.72. Labcorp Holdings' value of 14.31 is 2.8% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #56 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' EV-to-EBITDA compare to DGX and GH?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #56 out of 117 companies for EV-to-EBITDA. This puts Labcorp Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 14.72. Labcorp Holdings' value of 14.31 is 2.8% below this benchmark. Historically, Labcorp Holdings' own EV-to-EBITDA has ranged from 5.78 to 18.50 over the past decade. While the company's 10-year median is 11.41 vs. the industry median of 14.72, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.72, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current EV-to-EBITDA of 14.31 is 2.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labcorp Holdings. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current EV-to-EBITDA is 14.31, which is 25% above median its own 10-year median of 11.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Fairly Valued. The stock's GF Value™ is $270.12, compared to a current price of $282.00 — trading 4.4% above its estimated fair value. The current EV-to-EBITDA is 14.31, which is 25% above median its 10-year median of 11.41 and 2.8% below the Medical Diagnostics & Research industry median of 14.72. Labcorp Holdings' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current EV-to-EBITDA is 14.31 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $282.00 is trading 4.4% above its estimated GF Value™ of $270.12.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for LTS:0JSY:
EV-to-EBITDA: 14.31 (25% above median its 10-year median of 11.41)
GF Value™: $270.12 vs. price of $282.00 (4.4% above fair value)
Industry Position: 2.8% below the Medical Diagnostics & Research median (#56 of 117)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
80GF Score
Get the complete analysis for LTS:0JSY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
